Medicago, Inc. (MDG.TO)

Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies comprising the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 and seasonal influenza vaccines. The company has a partnership with Philip Morris International to explore new opportunities in tobacco adjacent businesses; and research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Medicago Inc. was incorporated in 1997 and is headquartered in Quebec, Canada.